A blockbuster cancer drug? TYK’s claims go under the microscope
The medicines company released scanty but promising results for an experimental drug just as its shares were joining the Hong Kong Stock Connect scheme Key Takeaways: The drug being developed…
Earnings blow for CSPC Pharma as the state drives a hard bargain
The generic drugs giant has warned of a 26% slide in annual profits after China’s national healthcare system imposed big price cuts on qualifying medicines Key Takeaways: CSPC Pharma…
AstraZeneca could face limited fallout from Chinese tax probe
The drugs giant and one of its top executives are being investigated over business tactics in China, but a potential fine for one alleged offence would not break the bank…
A McDonald’s Valuation Downsize, and New Medical Plan Additions
The value of McDonald's China operation has plunged by more than half in the last year. And 91 companies got their drugs added to China's national health plan By Doug…
NEWS WRAP: AstraZeneca China president assisting in investigation
The British drugmaker said Leon Wang is currently cooperating with an ongoing probe, as media reported the case involved the defrauding of China’s national insurance fund By A. Au…
Will Genscript cash out of Legend Biotech in the face of fat profit temptation?
A potential sale of Legend Biotech may carry a 30% to 50% premium, which could generate up to 55.8 billion yuan for Genscript based on its 48% stake in the…
FAST NEWS: Gracell shareholders approve merger with AstraZeneca
The latest: Gracell Biotechnologies Inc. (GRCL.US) announced Tuesday that its shareholders approved the company’s sale to AstraZeneca (AZN.L) at an extraordinary general meeting on Feb. 19. Looking up: Gracell’s merger with…
Recent Articles
RELATED ARTICLES
-
Alibaba’s breakup in tatters, could 2025 be the year of asset shedding?
9988.HK BABA.US -
Everest Medicines eyes mRNA tumor vaccines as drug valuations rebound
1952.HK
-
Sun Art pursues life after Alibaba in China’s evolving retail landscape
6808.HK
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
Vipshop gets left behind in China tech stock rally
VIPS.US
-
Two Autonomous Driving IPOs, and Alibaba Sheds a ‘New Retail’ Asset
WRD.US 9660.HK
-
East Buy ends superstar influencer addiction – but at a big price
1797.HK
